Latest updates
View our press releases and follow Diasome’s path to Phase III Clinical Trials.
Press Release
July 5, 2017
Diasome Pharmaceuticals, Inc. Receives Funding From JDRF T1D Fund
Learn More
Press Release
July 5, 2017
Diasome Pharmaceuticals, Inc. Receives Funding From JDRF T1D Fund
Learn More
Press Release
July 5, 2017
Diasome Pharmaceuticals, Inc. Receives Funding From JDRF T1D Fund
Learn More
Press Release
July 5, 2017
Diasome Pharmaceuticals, Inc. Receives Funding Led By Medicxi
Learn More
Press Release
July 5, 2017
Diasome Pharmaceuticals, Inc. Receives Funding Led By Medicxi
Learn More
Press Release
July 5, 2017
Diasome Pharmaceuticals, Inc. Receives Funding Led By Medicxi
Learn More
Interview
October 17, 2016
2016 Diabetes Symposium in Boston, Robert Geho interviewed by Diabetes in Control publisher Steve Freed
Learn More
Interview
October 17, 2016
2016 Diabetes Symposium in Boston, Robert Geho interviewed by Diabetes in Control publisher Steve Freed
Learn More
Interview
October 17, 2016
2016 Diabetes Symposium in Boston, Robert Geho interviewed by Diabetes in Control publisher Steve Freed
Learn More
News Article
August 28, 2016
After Decades of work, Diasome's insulin additive enters 200-patient trial
Learn More
News Article
August 28, 2016
After Decades of work, Diasome's insulin additive enters 200-patient trial
Learn More
News Article
August 28, 2016
After Decades of work, Diasome's insulin additive enters 200-patient trial
Learn More
Press Release
July 29, 2016
Diasome announces dosing of first type 1 diabetes patient in randomized phase 2b clinical trial of injectable hepatocyte direct vesicle (HDV) technology with insulin
Learn More
Press Release
July 29, 2016
Diasome announces dosing of first type 1 diabetes patient in randomized phase 2b clinical trial of injectable hepatocyte direct vesicle (HDV) technology with insulin
Learn More
Press Release
July 29, 2016
Diasome announces dosing of first type 1 diabetes patient in randomized phase 2b clinical trial of injectable hepatocyte direct vesicle (HDV) technology with insulin
Learn More
Press Release
March 15, 2016
Diasome Pharmaceuticals, Inc. and Lyfebulb, LLC Announce Partnership
Learn More
Press Release
March 15, 2016
Diasome Pharmaceuticals, Inc. and Lyfebulb, LLC Announce Partnership
Learn More
Press Release
March 15, 2016
Diasome Pharmaceuticals, Inc. and Lyfebulb, LLC Announce Partnership
Learn More
Press Release
April 27, 2015
Clinical trial design collaboration with Joslin Diabetes Center
Learn More
Press Release
April 27, 2015
Clinical trial design collaboration with Joslin Diabetes Center
Learn More
Press Release
April 27, 2015
Clinical trial design collaboration with Joslin Diabetes Center
Learn More
Press Release
March 31, 2015
Injected HDV insulin patent allowance
Learn More
Press Release
March 31, 2015
Injected HDV insulin patent allowance
Learn More
Press Release
March 31, 2015
Injected HDV insulin patent allowance
Learn More
Press Release
February 25, 2015
Oral insulin technology patent issues
Learn More
Press Release
February 25, 2015
Oral insulin technology patent issues
Learn More
Press Release
February 25, 2015
Oral insulin technology patent issues
Learn More
Journal Article
May 1, 2014
The importance of the liver in insulin replacement therapy in insulin-deficient diabetes
Learn More
Journal Article
May 1, 2014
The importance of the liver in insulin replacement therapy in insulin-deficient diabetes
Learn More
Journal Article
May 1, 2014
The importance of the liver in insulin replacement therapy in insulin-deficient diabetes
Learn More
Press Release
April 9, 2014
McDonald Partners Engagement
Learn More
Press Release
April 9, 2014
McDonald Partners Engagement
Learn More
Press Release
April 9, 2014
McDonald Partners Engagement
Learn More
Study Summary
February 27, 2014
A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral anti-diabetic treatment in patients with type 2 diabetes mellitus
Learn More
Study Summary
February 27, 2014
A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral anti-diabetic treatment in patients with type 2 diabetes mellitus
Learn More
Study Summary
February 27, 2014
A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral anti-diabetic treatment in patients with type 2 diabetes mellitus
Learn More
Media Relations
Cherilyn Cecchini, M.D.
LifeSci Public Relations
+1.646.876.7110
ccecchini@lifescipublicrelations.com
